Pfizer, FDA Updating Pregnancy Caution On Zoloft Label

By Sindhu Sundar (September 18, 2015, 9:35 PM EDT) -- Pfizer Inc. is in talks with the U.S. Food and Drug Administration to update the label on its antidepressant Zoloft to acknowledge studies showing increased heart defect risks in children whose mothers took the drug early in their pregnancies, but the drugmaker stressed Friday that the proposal was not prompted by new data or litigation.

Pfizer says the proposed label change on Zoloft was prompted by an FDA move to revamp pregnancy labeling on all prescription drugs. (Credit: AP) The drugmaker, which is fielding multidistrict litigation in Pennsylvania federal court over cardiac birth defect risks, said the proposed label change was...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!